

FOR IMMEDIATE RELEASE

Dr. Gries Joins ASCPT Board of Directors

Alexandria, Va. (January 26, 2018) — Jean–Michel Gries, MBA, PhD, PharmD, has joined the American Society for Clinical Pharmacology and Therapeutics (ASCPT) Board of Directors. He will begin a 3-year term as At-Large Director in 2018.

Dr. Gries is Vice President of Early Phase Development at PAREXEL International. From 2012 to 2015, he was Vice President and General Manager of Early Clinical Development at Covance. He also served as Vice President and Head of R&D in the Pharmaceutical Products Division of Alcon from 2009 to 2011.

Dr. Gries is a business leader with more than 20 years of experience in clinical pharmacology, pharmaceutical product development, and licensing. He has helped facilitate hundreds of applications for investigational and new drugs across many therapeutic areas, including oncology, central nervous system disorders, inflammation, and ophthalmology.

For ASCPT, Dr. Gries has served on the Membership, Nominating, and Education Committees and chaired the Pharmacometrics Scientific Section. He was a member of the Immunetrics Board of Directors from 2004 to 2008 and participated on the American College of Clinical Pharmacology's (ACCP) Finance and Membership Committees. He is a current member of the *Biomarkers in Medicine* Editorial Board.

Dr. Gries received the Presidential Trainee Award from ASCPT in 1996. For three consecutive years, he was presented with the Covance, Inc. Business Unit of the Year Award for Early Clinical Development. He is also an ACCP Fellow and was an ACCP Regent from 2009 to 2013.

Dr. Gries earned his MBA in finance from the Wharton School. He received his PhD in pharmacokinetics and his PharmD from the Paris Descartes University, France. From 1993 to 1997, he studied under Dr. Lewis Sheiner as a research fellow at the University of California, San Francisco.

About ASCPT

ASCPT is the leading forum for the discussion, development, and integration of clinical pharmacology, translational medicine, and therapeutics. Headquartered in Alexandria, Va., ASCPT was established in 1900. Today, more than 2,400 ASCPT members are committed to advancing the science and practice of translational medicine.

Contact:

Sharon Swan, FASAE, CAE
CEO, ASCPT
703-836-6981
Sharon@ascpt.org